Bioasis Technologies

Bioasis Technologies EPS

The Earnings per Share (EPS) of Bioasis Technologies (BIOAF) as of Oct 20, 2026 is -0.04 CAD. In the previous year, Earnings per Share (EPS) was 0.01 CAD — a change of -500.04% (lower).

EPS

-0.04CAD

YoY

-500.04%

Last updated:

Earnings per Share (EPS) of Bioasis Technologies is 2022 -0.04 CAD. Earnings per Share (EPS) of Bioasis Technologies was 2021 0.01 CAD. It decreases by -500.04% lower compared to the previous year.

The Bioasis Technologies EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2018
-0.10 CAD
Jan 1, 2019
-0.06 CAD
Jan 1, 2020
-0.07 CAD
Jan 1, 2021
0.01 CAD
Jan 1, 2022
-0.04 CAD
Jan 1, 2023 (e)
-0.07 CAD
Jan 1, 2024 (e)
-0.07 CAD
Jan 1, 2025 (e)
-0.07 CAD
The Bioasis Technologies EPS history
YEAREPSYoY
est-0.07CAD0.00%
est-0.07CAD0.00%
est-0.07CAD+75.78%
-0.04CAD-500.04%
0.01CAD-115.74%
-0.07CAD+6.29%
-0.06CAD-41.23%
-0.10CAD+58.35%
-0.07CAD+13.74%
-0.06CAD-12.37%
-0.07CAD-25.25%
-0.09CAD-32.30%
-0.13CAD+44.64%
-0.09CAD+19.87%
-0.08CAD-9.33%
-0.08CAD+24.07%
-0.07CAD+53.96%
-0.04CAD+1,200.00%
-0.00CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioasis Technologies Stock analysis

What does Bioasis Technologies do? biOasis Technologies, Inc. generates revenue by developing therapeutics using its proprietary xB3 platform, which is designed to deliver treatments across the blood brain barrier for central nervous system disorders. The company focuses on areas of high unmet medical need, specifically targeting brain cancers and neurodegenerative diseases. This technology leverages a human transport protein found circulating at low levels in the blood to shuttle molecules to their targets within the brain via receptor-mediated transcytosis. The firm markets its in-house development programs aimed at creating both symptomatic and disease-modifying treatments for brain-related diseases and disorders. By utilizing the xB3 platform, biOasis Technologies, Inc. addresses specific therapeutic challenges in the central nervous system, offering solutions for conditions that currently lack adequate medical interventions. The business model relies on the efficacy of this delivery system to reach targets within the brain, serving the needs of patients suffering from these severe neurological conditions. Bioasis Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioasis Technologies stock

Earnings per Share (EPS) of Bioasis Technologies is -0.04 CAD in 2022.

Earnings per Share (EPS) of Bioasis Technologies changed from 0.01 CAD to -0.04 CAD, representing a -500.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Bioasis Technologies since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Bioasis Technologies

All Key Metrics — Bioasis Technologies